Holen Sie sich die Stockscreener-App
5.02
0.40%
0.02
Handel nachbörslich:
5.02
Schlusskurs vom Vortag:
$5.00
Offen:
$5.01
24-Stunden-Volumen:
1.52M
Relative Volume:
1.38
Marktkapitalisierung:
$367.70M
Einnahmen:
$31,000
Nettoeinkommen (Verlust:
$-38.18M
KGV:
-7.1612
EPS:
-0.701
Netto-Cashflow:
$-38.90M
1W Leistung:
+12.05%
1M Leistung:
+1.62%
6M Leistung:
-8.23%
1J Leistung:
+4.15%
1-Tages-Spanne:
$5.01
$5.205
1-Wochen-Bereich:
$4.65
$5.205
52-Wochen-Spanne:
$4.25
$7.25
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.02 | 366.23M | 31,000 | -38.18M | -38.90M | -0.701 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Eingeleitet | Stephens | Overweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance UK
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Candel Therapeutics (CADL) director granted 4,618 fully vested stock options - Stock Titan
Director at Candel Therapeutics (NASDAQ: CADL) gets 2,795 options - Stock Titan
Candel Therapeutics (CADL) director granted fully vested stock options in lieu of cash fees - Stock Titan
Candel gives five new hires options for 70,000 shares at $4.90 - Stock Titan
CADL Forecast, Price Target & Analyst Ratings | CANDEL THERAPEUTICS INC (NASDAQ:CADL) - ChartMill
CADL Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Purchases Worth US$3.00m See Losses As Candel Therapeutics Market Value Drops To US$352m - simplywall.st
Candel gains on additional mid-stage trial data for lead asset - MSN
Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics - Barchart.com
Paul Manning holds 7.9% of Candel Therapeutics (NASDAQ: CADL) shares - Stock Titan
Buy Signal: Should I hold or sell Candel Therapeutics Inc nowQuarterly Investment Review & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data By Investing.com - Investing.com Australia
Will Candel Therapeutics Inc outperform small cap indexesWall Street Watch & Weekly High Conviction Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Candel stock rating on lung cancer data - Investing.com
Candel Therapeutics prices $100M public offering at $5.45 per share - MSN
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Market movers: Uber, Getty Images, Candel Therapeutics... - Proactive Investors
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409 - Proactive financial news
Candel reports extended survival data for lung cancer therapy - Investing.com
Candel Therapeutics Inc extended survival tail observed in trial of aglatimagene besadenovec - marketscreener.com
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - Bitget
Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec - TradingView
Candel Therapeutics Reports Extended Survival Tail Observed - GlobeNewswire
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (Can-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors - marketscreener.com
Aug Drivers: Is Candel Therapeutics Inc stock forming a triangle pattern2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
FY2030 Earnings Forecast for CADL Issued By HC Wainwright - MarketBeat
Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7% - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revvity (RVTY) and Candel Therapeutics (CADL) - The Globe and Mail
Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL - MarketBeat
Restrictive RTW Purchase Agreement Covenants Threaten Candel Therapeutics’ Financial Flexibility and Increase Default Risk - The Globe and Mail
Responsive Playbooks and the CADL Inflection - Stock Traders Daily
Citigroup Cuts Candel Therapeutics (NASDAQ:CADL) Price Target to $22.00 - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Candel Therapeutics stock rating at buy - Investing.com
Small cap wrap: 374Water, Ideal Power, Northstar Gold, Candel Therapeutics… - Proactive financial news
Candel Therapeutics (NASDAQ:CADL) Issues Quarterly Earnings Results, Misses Expectations By $0.30 EPS - MarketBeat
Candel Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances - Yahoo Finance
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights - Bitget
Candel Therapeutics, Inc. announces financial results for the fourth quarter and full year of fiscal 2025, along with recent strategic updates. - Bitget
CADL: Pivotal trials and BLA submission planned for 2026, with strong financial runway into 2028 - TradingView
BRIEF-Candel Therapeutics Q4 Net Income USD -29.496 Million - TradingView
Funding extends Candel Therapeutics (NASDAQ: CADL) cash runway into early 2028 - Stock Titan
Tech Rally: Is Candel Therapeutics Inc stock suitable for long term investing2026 Momentum Check & Real-Time Stock Price Movement Reports - baoquankhu1.vn
Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research - MarketBeat
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Option Exercise |
1.29 |
937 |
1,209 |
53,430 |
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):